参考文献
1: Linagliptin. Avoid gliptins! Prescrire Int. 2013 Feb;22(135):36-7. Review. PubMed PMID: 23444496.
2: Brown DX, Choudhury M, Evans M. Linagliptin as add-on therapy for type 2 diabetes - an overview. Drugs Today (Barc). 2012 Oct;48(10):645-54. doi: 10.1358/dot.2012.48.10.1860771. Review. PubMed PMID: 23110260.
3: Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2012 Sep 10;72(13):1793-824. doi: 10.2165/11209570-000000000-00000. Review. Erratum in: Drugs. 2013 Jan;73(1):99. PubMed PMID: 22913735.
4: Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012 Jul 1;51(7):411-27. doi: 10.2165/11630900-000000000-00000. Review. PubMed PMID: 22568694.
5: Ohmura T, Hayashi N, Encinas J. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)]. Nihon Yakurigaku Zasshi. 2012 Apr;139(4):174-83. Review. Japanese. PubMed PMID: 22498683.
6: Neumiller JJ, Setter SM. Review of linagliptin for the treatment of type 2 diabetes mellitus. Clin Ther. 2012 May;34(5):993-1005. doi: 10.1016/j.clinthera.2012.02.029. Epub 2012 Mar 21. Review. PubMed PMID: 22440191.
7: Agrawal R, Jain P, Dikshit SN. Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor. Curr Drug Targets. 2012 Jun;13(7):970-83. Review. PubMed PMID: 22420306.
8: Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2012 Aug;14(8):694-708. doi: 10.1111/j.1463-1326.2012.01586.x. Epub 2012 Mar 20. Review. PubMed PMID: 22340363.
9: Neumiller JJ. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2012 Mar;46(3):358-67. doi: 10.1345/aph.1Q522. Epub 2012 Feb 7. Review. PubMed PMID: 22318932.
10: Forst T, Pfützner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother. 2012 Jan;13(1):101-10. doi: 10.1517/14656566.2012.642863. Review. PubMed PMID: 22149370.
